Valuation: RaySearch Laboratories AB

Market Cap 616.75Cr 65Cr 56Cr 53Cr 48Cr 91Cr 6.19TCr 92Cr 242.07Cr 3.1TCr 244.38Cr 239.03Cr 10TCr P/E 2026 *
23.1x
P/E 2027 * 18.9x
Enterprise Value 633.65Cr 67Cr 58Cr 54Cr 50Cr 93Cr 6.36TCr 95Cr 248.7Cr 3.19TCr 251.07Cr 245.58Cr 11TCr EV / Sales 2026 *
4.54x
EV / Sales 2027 * 3.8x
Free-Float
80.09%
Yield 2026 *
2.22%
Yield 2027 * 2.65%
1 day+11.87%
1 month-10.96%
3 months-23.45%
6 months-18.04%
Current year-20.80%
1 month 16.85
Extreme 16.85
24
Current year 16.85
Extreme 16.85
24.62
1 year 16.85
Extreme 16.85
30.75
3 years 8
Extreme 8
37.36
5 years 4.04
Extreme 4.039
37.36
10 years 4.04
Extreme 4.039
37.36
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2000
Director of Finance/CFO 48 27/01/2025
Chief Tech/Sci/R&D Officer 53 28/08/2015
Director TitleAgeSince
Director/Board Member 57 01/01/2000
Chairman 81 18/11/2016
Chairman 87 30/09/2022
Change 5-day change 1-year change 3-year change Capi.($)
+11.87%-.--% - - 65Cr
+5.82%+13.10%-17.62%+17.10% 3.74TCr
-1.07%+8.55%-44.95%+147.90% 1.3TCr
+1.06%+0.07%-24.59%+63.05% 543.61Cr
+5.99%+14.23% - - 248.55Cr
+3.31%+2.50% - - 183.96Cr
+1.80%+4.07%+18.63%-43.60% 167.91Cr
+0.08%-2.57%-36.05% - 102.08Cr
+1.98%+6.68%+36.18%+120.48% 91Cr
-1.36%+1.68%-37.84%-46.77% 83Cr
Average +2.95%+5.27%-15.18%+43.02% 718.21Cr
Weighted average by Cap. +3.71%+10.10%-22.90%+48.95%

Financials

2026 *2027 *
Net sales 139.6Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.4TCr 21Cr 55Cr 702.66Cr 55Cr 54Cr 2.32TCr 163.05Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.64TCr 24Cr 64Cr 820.69Cr 65Cr 63Cr 2.71TCr
Net income 26Cr 2.8Cr 2.42Cr 2.26Cr 2.07Cr 3.9Cr 266.12Cr 3.96Cr 10Cr 133.38Cr 11Cr 10Cr 440.96Cr 32Cr 3.38Cr 2.92Cr 2.73Cr 2.5Cr 4.71Cr 321.35Cr 4.78Cr 13Cr 161.07Cr 13Cr 12Cr 532.48Cr
Net Debt 17Cr 1.78Cr 1.54Cr 1.44Cr 1.32Cr 2.49Cr 169.71Cr 2.52Cr 6.63Cr 85Cr 6.7Cr 6.55Cr 281.22Cr 2.5Cr 26.38L 22.82L 21.31L 19.55L 36.77L 25Cr 37.35L 98.12L 13Cr 99.06L 96.89L 42Cr
Logo RaySearch Laboratories AB
RaySearch Laboratories AB (publ) is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Employees
465
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
179.90SEK
Average target price
310.00SEK
Spread / Average Target
+72.32%

Quarterly revenue - Rate of surprise